Anal Cancer News and Research

RSS

Anal cancer is a type of cancer which arises from the anus, the distal orifice of the gastrointestinal tract. It is a distinct entity from the more common colorectal cancer.

Phase III data reveals potential of Merck’s GARDASIL in preventing HPV and HPV-related cancers

Merck & Co., Inc. announced today that in new Phase III data, GARDASIL® [Human Papillomavirus Quadrivalent (Types 6, 11, 16 and 18) Vaccine, Recombinant] was 77.5 percent (95 percent CI: 39.6, 93.3) efficacious against anal intraepithelial neoplasia (AIN) associated with human papillomavirus (HPV) types 6, 11, 16 and 18 in 16-to-26 year-old men who have sex with men. The data were presented at the European Research Organization on Genital Infection and Neoplasia (EUROGIN) conference in Monte Carlo, Monaco.

18 Feb 2010

Phase III study: GARDASIL prevents 77.5% of pre-cursor lesions to anal cancer

In a new phase III study, GARDASIL(R) (Quadrivalent Human Papillomavirus (Types 6, 11, 16 and 18) Recombinant Vaccine) prevented 77.5 per cent of anal intraepithelial neoplasia (AIN) associated with human papillomavirus (HPV) types 6, 11, 16 and 18 in 16-to-26 year-old men who have sex with men.

17 Feb 2010

IMRT and extensive safety measures can prevent radiation injuries in cancer patients, says oncology expert

Recent media stories have reported isolated cases of cancer patients who were injured by incorrect doses from intensity-modulated radiation therapy (IMRT).

2 Feb 2010

Advaxis to collaborate with GOG in Phase II clinical trial of ADXS11-001

Advaxis, Inc., the live, attenuated Listeria monocytogenes (Lm) vaccine company, will collaborate with the Gynecologic Oncology Group (GOG), a collaborative research group of the National Cancer Institute (NCI), in a multicenter, Phase II clinical trial of the Company’s lead drug candidate, ADXS11-001 in the treatment of advanced cervix cancer in women who have failed prior cytotoxic therapy.

15 Dec 2009

Epitope spreading can get triggered by live, attenuated Listeria vaccine

Advaxis, Inc. (OTCBB: ADXS), the live, attenuated Listeria monocytogenes (Lm) vaccine company, in collaboration with its scientific founder and Scientific Advisory Board Chair Dr. Yvonne Paterson, have shown that epitope spreading occurs in response to a form of the Company’s proprietary technology that targets tumor blood vessels (anti angiogenic antigen).

8 Oct 2009

Swinging 60s saw a rise in HPV related cancers

Rates for cancers linked to a sexually-transmitted virus have increased in the post World War II baby boomer generation according to new research published in the British Journal of Cancer (Wednesday February 4).

5 Feb 2009

Immunogenicity and safety of human papillomavirus vaccine in healthy boys

New industry-supported research from Finland suggests that Cervarix, an HPV vaccine given to girls in Europe and elsewhere, is safe for boys as well.

21 Dec 2008

Comprehensive assessment of burden of HPV-associated cancers in the U.S.

Professor Vivien Chen, PhD,. Associate Professor Xiao Cheng Wu, MD, PhD and Assistant Professor Edward Peters, DMD, SM, ScD, at LSU Health Sciences Center New Orleans School of Public Health contributed five papers to the largest most comprehensive assessment of the burden of human papillomavirus (HPV)-associated cancers in the United States to date.

11 Nov 2008

Study finds increased risk of some cancers among HIV-positive people in U.S.

HIV-positive people in the U.S., many of whom are living longer because of antiretroviral drugs, are at an increased risk for certain types of cancers, according to a study published Tuesday in the Annals of Internal Medicine, Reuters reports.

22 May 2008

Cisplatin found to be less effective than standard treatment for patients with anal cancer

When administered before chemoradiation, the common anti-cancer drug cisplatin neither improved disease-free survival nor reduced the number of colostomies needed when compared to the standard treatment for patients with anal canal cancer, according to a study published in the April 23 issue of the JAMA, the Journal of the American Medical Association.

22 Apr 2008

Bones rendered more vulnerable following radiation therapy

Researchers have found that mice who were given one therapeutic dose of radiation equal to that received by human cancer patients, lost as much as 39 percent of the spongy portion of their inner bone.

12 Jul 2006

$Radiotherapy for certain cancers increases the risk of pelvic fractures$

Radiotherapy for certain cancers increases the risk of pelvic fractures

A new study suggests that older women who receive pelvic radiation treatment for cervical, anal or rectal cancer may have an increased risk of pelvic fracture.

24 Nov 2005

Antiretroviral therapy may prevent excess risk of some cancers in people with HIV

In people infected with human immunodeficiency virus (HIV), highly active anti-retroviral therapy (HAART) may prevent most excess cases of Kaposi sarcoma and non-Hodgkin lymphoma, according to a new study in the March 16 issue of the Journal of the National Cancer Institute.

18 May 2005

Antiretroviral therapy may prevent some cancers in people with HIV

In people infected with human immunodeficiency virus (HIV), highly active antiretroviral therapy (HAART) may prevent most excess cases of Kaposi sarcoma and non-Hodgkin lymphoma, according to a new study in the March 16 issue of the Journal of the National Cancer Institute.

15 Mar 2005

Anal cancer is on the rise in both sexes

Anal cancer is on the rise in both sexes, particularly among American men, and changing trends in sexual behavior — combined with current tobacco use and infection by a specific strain of the human papillomavirus — may help explain the increase.

9 Jul 2004